Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PBLA 
Panbela Therapeutics Inc (PBLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PBLA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -77.18% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.65M USD | Price to earnings Ratio - | 1Y Target Price 500 |
Price to earnings Ratio - | 1Y Target Price 500 | ||
Volume (30-day avg) 22770 | Beta 0.95 | 52 Weeks Range 0.30 - 1.11 | Updated Date 04/1/2025 |
52 Weeks Range 0.30 - 1.11 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -34.51 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -229.77% | Return on Equity (TTM) -798.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7852637 | Price to Sales(TTM) - |
Enterprise Value 7852637 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.22 | Shares Outstanding 4854830 | Shares Floating 4854782 |
Shares Outstanding 4854830 | Shares Floating 4854782 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 4 | Target Price 23.5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Panbela Therapeutics Inc
Company Overview
History and Background
Panbela Therapeutics, Inc. (PBLA) is a clinical stage biopharmaceutical company focused on developing disruptive therapeutics for patients with cancer. Founded in 2011, it has primarily focused on advancing its lead product candidate, ivospemin (SBP-101), through clinical trials.
Core Business Areas
- Drug Development: Focuses on the research and development of new therapeutic drugs for cancer treatment.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Prepares for the potential commercialization of approved drugs, including manufacturing, marketing, and distribution.
Leadership and Structure
The leadership team includes Jennifer K. Simpson, PhD, as the Chief Executive Officer and President. The organizational structure is typical of a clinical-stage biotech company, with departments dedicated to R&D, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Ivospemin (SBP-101): Ivospemin (SBP-101) is Panbela's lead investigational compound being developed for desmoplastic tumors such as pancreatic cancer. As a clinical-stage drug, it does not yet have market share. Competitors developing pancreatic cancer therapies include companies like Eli Lilly and Company (Gemzar), and other companies with therapies in various stages of clinical trials. Market size for pancreatic cancer treatments is substantial and growing.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing innovative therapies for unmet medical needs. Pancreatic cancer treatment is an area of significant unmet need. The industry is characterized by long development timelines, high costs, and regulatory hurdles.
Positioning
Panbela is a clinical-stage company focused on the development of ivospemin (SBP-101) for the treatment of desmoplastic tumors, with a primary focus on pancreatic cancer. Their positioning relies on the potential for ivospemin to address limitations of existing therapies. Competitive advantages could stem from demonstrating superior efficacy or safety profiles in clinical trials.
Total Addressable Market (TAM)
The global pancreatic cancer therapeutics market is expected to reach billions of dollars. Panbela's positioning depends on the success of their clinical trials and the ability to capture a portion of this market with ivospemin.
Upturn SWOT Analysis
Strengths
- Lead drug candidate targeting a significant unmet need (pancreatic cancer)
- Experienced management team in drug development
- Potential for breakthrough therapy designation
- Strong intellectual property portfolio
Weaknesses
- Clinical stage company with no currently marketed products
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion into other cancer indications
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other companies developing pancreatic cancer therapies
- Patent challenges
- Economic downturn affecting funding availability
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
Competitive Landscape
Panbela's competitive advantage hinges on the efficacy and safety of ivospemin compared to existing therapies and other drugs in development. The company faces significant competition from larger pharmaceutical companies with greater resources and established market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: As a clinical stage company, historical growth is primarily measured by progress in clinical trials rather than revenue or profit growth.
Future Projections: Future growth is contingent upon successful clinical trial outcomes, regulatory approvals, and potential commercialization of ivospemin. Analyst projections will depend on the company's milestones and the perceived market potential.
Recent Initiatives: Recent initiatives focus on advancing clinical trials for ivospemin (SBP-101) in pancreatic cancer and other indications.
Summary
Panbela Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company focused on addressing unmet needs in cancer treatment, particularly pancreatic cancer. Its success heavily relies on the positive outcomes of its clinical trials and the potential commercialization of its lead drug candidate. While it has a strong intellectual property position, it faces financial constraints and strong competition from larger, more established pharmaceutical companies. Investors should closely monitor clinical trial results and regulatory developments.
Similar Companies
- CLVS
- ZYME
- ASMB
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company press releases
- Analyst reports
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and assessment of risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Panbela Therapeutics Inc
Exchange NASDAQ | Headquaters Waconia, MN, United States | ||
IPO Launch date 2017-01-03 | CEO, President & Director Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.panbela.com |
Full time employees 7 | Website https://www.panbela.com | ||
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.